In the last trading session, 28.39 million Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares changed hands as the company’s beta touched 0.82. With the company’s per share price at $9.00 changed hands at -$0.28 or -3.02% during last session, the market valuation stood at $3.52B. RXRX’s last price was a discount, traded about -74.89% off its 52-week high of $15.74. The share price had its 52-week low at $5.60, which suggests the last value was 37.78% up since then.
Analysts gave the Recursion Pharmaceuticals Inc (RXRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.43. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended RXRX as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Recursion Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.42.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Instantly RXRX was in red as seen at the end of in last trading. With action -14.53%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 33.14%, with the 5-day performance at -14.53% in the red. However, in the 30-day time frame, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is 19.52% up.
The consensus price target for the stock as assigned by Wall Street analysts is 11, meaning bulls need an upside of 18.18% from its current market value. According to analyst projections, RXRX’s forecast low is 6 with 12 as the target high. To hit the forecast high, the stock’s price needs a -33.33% plunge from its current level, while the stock would need to tank 33.33% for it to hit the projected low.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
Year-over-year growth is forecast to reach 52.11% up from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 19.04M. 3 analysts are of the opinion that Recursion Pharmaceuticals Inc’s revenue for the current quarter will be 12M. The company’s revenue for the corresponding quarters a year ago was 10.89M and 13.79M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 74.85%. The estimates for the next quarter sales put growth at -13.01%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -43.41%. The 2025 estimates are for Recursion Pharmaceuticals Inc earnings to increase by 2.61%, but the outlook for the next 5-year period is at 4.49% per year.
RXRX Dividends
Recursion Pharmaceuticals Inc is expected to release its next quarterly earnings report in March.
BAILLIE GIFFORD & CO holds the second largest percentage of outstanding shares, with 10.9787% or 26.59 million shares worth $199.42 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF . With 18.28 shares estimated at $164.5 million under it, the former controlled 4.76% of total outstanding shares. On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF held about 3.00% of the shares, roughly 11.51 shares worth around $103.57 million.
